Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders

Blood

Volumn 113, Issue 23, 2009, Pages 5942-5950

  Ishii, Takefumi ^a   Wang, Jiapeng ^a   Zhang, Wei ^a   Mascarenhas, John ^a   Hoffman, Ronald ^a,b   Dai, Ying ^a   Wisch, Nathaniel ^a   Xu, Mingjiang ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Myeloproliferative Disorder Research Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; HISTAMINE; INTERLEUKIN 31; INTERLEUKIN 8; LEUKOTRIENE; PROSTAGLANDIN D2; ACTIN; IL31 PROTEIN, HUMAN; INTERLEUKIN 4; INTERLEUKIN DERIVATIVE; JANUS KINASE 2; NERVE GROWTH FACTOR; TRYPTASE;

ARTICLE; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; HISTAMINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; MAST CELL; MYELOPROLIFERATIVE DISORDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PRURITUS; ALLELE; BIOSYNTHESIS; BLOOD; CELL MOTION; CYTOLOGY; METABOLISM; PATHOLOGY;

ACTINS; ALLELES; CELL MOVEMENT; HISTAMINE; HUMANS; INTERLEUKIN-4; INTERLEUKINS; JANUS KINASE 2; LEUKOTRIENES; MAST CELLS; MYELOPROLIFERATIVE DISORDERS; NERVE GROWTH FACTOR; PROSTAGLANDIN D2; TRYPTASES;

EID: 67651120136     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-179416     Document Type: Article

References (47)

1. Greaves MW. Recent advances in pathophysiology and current management of itch. Ann Acad Med Singapore. 2007;36:788-792. (Pubitemid 350219088)
2. Ständer S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol. 2003;139:1463-1470. (Pubitemid 37441284)
3. Wiesner-Menzel L, Schulz B, Vakilzadeh F, et al. Electron microscopal evidence for a direct contact between nerve fibres and mast cells. Acta Derm Venereol. 1981;61:465-469. (Pubitemid 12246779)
4. Xiang Z, Nilsson G. IgE receptor-mediated release of nerve growth factor by mast cells. Clin Exp Allergy. 2000;30:1379-1386. (Pubitemid 30765645)
5. Bell JK, McQueen DS, Res JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol. 2004;142:374-380.
6. Steinhoff M, Vergnolle NM, Young SH, Tognetto M, Amadesi S, Ennes HS. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 2000;6:151-158. (Pubitemid 30082358)
7. Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752-760. (Pubitemid 39023308)
8. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411-417. (Pubitemid 43192023)
9. Hoffman R, Xu M, Finazzi G, Barbui T. The polycythemias. In: Hoffman R, Benz E, Shattil S, Furie B, Silberstein L, McGlave P, Heslop H, eds. Hematology: Basic Principles and Practice (5th Ed). Philadelphia, PA: Churchill Livingstone; 2008:1073-1108.
10. Mesa RA. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int J Hematol. 2002;76:193-203.
11. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68-76. (Pubitemid 46120195)
12. Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Hematol. 2001;115:619-621. (Pubitemid 34015654)
13. Abdel-Naser MB, Gollnick H, Orfanos CE. Aquagenic pruritus as a presenting symptom of polycythemia vera. Dermatology. 1993;187:130-133. (Pubitemid 23209583)
14. Gerlini G, Prignano F, Pimpinelli N. Acute leucocytoclastic vasculitis and aquagenic pruritus long preceding polycythemia rubra vera. Eur J Dermatol. 2002;12:270-271. (Pubitemid 34454658)
15. Gangat N, Strand JJ, Lasho TL, Li CY, Pardanani A, Tefferi A. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol. 2008;83:451-453. (Pubitemid 351742791)
16. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood. 2002;99:2627. (Pubitemid 34525462)
17. Wang J, Ishii T, Zhang W, et al. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. Leukemia. Prepublished on April 23, 2009, as DOI 10.1038/leu.2009.85.
18. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-ofcare diagnostic algorithms. Leukemia. 2008;22:14-22.
19. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108:3128-3134. (Pubitemid 44776953)
20. Ishii T, Zhao Y, Shi J, Sozer S, Hoffman R, Xu M. T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation. Leukemia. 2007;21:2433-2441. (Pubitemid 350148885)
21. Shi J, Zhao Y, Ishii T, et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res. 2007;67:6417-6424. (Pubitemid 47037526)
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method. Methods. 2001;25:402-408. (Pubitemid 34164012)
23. Kushnir-Sukhov NM, Gilfillan AM, Coleman JW, et al. 5-Hydroxytryptamine induces mast cell adhesion and migration. J Immunol. 2006;177:6422-6432. (Pubitemid 44628861)
24. Yang FC, Ingram DA, Chen S, et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest. 2003;112:1851-1861. (Pubitemid 38063708)
25. Tanaka A, Matsuda H. Expression of nerve growth factor in itchy skins of atopic NC/NgaTnd mice. J Vet Med Sci. 2005;67:915-919. (Pubitemid 41439652)
26. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol. 2001;117:977-983. (Pubitemid 33001220)
27. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res. 2006;34:97-115. (Pubitemid 43997964)
28. Kettner A, Kumar L, Antón IM, et al. WIP regulates signaling via the high affinity receptor for immunoglobulin E in mast cells. J Exp Med. 2004;199:357-368. (Pubitemid 38252048)
29. Webb DJ, Parsons JT, Horwitz AF. Adhesion assembly, disassembly and turnover in migrating cells: over and over and over again. Nat Cell Biol. 2002;4:E97-E100.
30. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061. (Pubitemid 40386783)
31. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397. (Pubitemid 40544655)
32. James C, Ugo V, Le Couedic JP, Staerk, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148. (Pubitemid 40663494)
33. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790. (Pubitemid 40570926)
34. Jackson N, Burt D, Crocker J, Boughton B. Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus. Br J Dermatol. 1987;116:21-29. (Pubitemid 17216801)
35. Abdel-Naser MB, Zaki MS, Mousa MH, et al. Cutaneous mononuclear cells and eosinophils are significantly increased after warm water challenge in pruritic areas of polycythemia vera. J Cutan Pathol. 2007;34:924-929.
36. Buchanan JG, Ameratunga RV, Hawkins RC. Polycythemia vera and water-induced pruritus: evidence against mast cell involvement. Pathology. 1994;26:43-45.
37. Gilbert HS, Warner RR, Wasserman LR. A study of histamine in myeloproliferative disease. Blood. 1966;28:795-806.
38. Steinman HK, Kobza-Black A, Lotti TM, Brunetti L, Panconesi E, Greaves MW. Polycythaemia rubra vera and water-induced pruritus: blood histamine levels and cutaneous fibrinolytic activity before and after water challenge. Br J Dermatol. 1987;116:329-333. (Pubitemid 17030536)
39. Arai I, Takano N, Hashimoto Y, et al. Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol. 2004;505:229-235. (Pubitemid 39535696)
40. Sugimoto M, Arai I, Futaki N, Hashimoto Y, Honma Y, Nakaike S. Increased scratching counts depend on a decrease in ability of cutaneous prostaglandin D2 biosynthesis in NC/Nga mice with atopic dermatitis. Exp Dermatol. 2005;14:898-905. (Pubitemid 41723207)
41. Sugimoto M, Arai I, Futaki N, et al. Putative mechanism of the itch-scratch circle: repeated scratching decreases the cutaneous level of prostaglandin D2, a mediator that inhibits itching. Prostaglandins Leukot Essent Fatty Acids. 2007;76:93-101. (Pubitemid 46217228)
42. Cooper B, Ahern D. Characterization of the platelet prostaglandin D2 receptor: loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders. J Clin Invest. 1979;64:586-590. (Pubitemid 9235004)
43. Hermouet S, Godard A, Pineau D, et al. Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. Cytokine. 2002;20:178-183. (Pubitemid 37163469)
44. Migliaccio AR, Martelli F, Verrucci M, et al. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol. 2008;36:158-171.
45. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487. (Pubitemid 34879335)
46. Bernardini N, Roza C, Sauer SK, Gomeza J, Wess J, Reeh PW. Muscarinic M2 receptors on peripheral nerve endings: a molecular target of antinociception. J Neurosci. 2002;22:RC229.
47. Arai I, Takaoka A, Hashimoto Y, et al. Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice. Eur J Pharmacol. 2007;556:207-214. (Pubitemid 46074005)